Asia Fresh News

Asia Fresh Stories

Archive for June 15th, 2015

XOS introduces HD Rocksand, a break-through technology for heavy metal detection in soil

leave a comment »

EAST GREENBUSH, N.Y., June 9, 2015 /PRNewswire/ — XOS (, a leading provider of mission-critical materials-analysis solutions for industries and regulators, announced today the release of its latest HDXRF® innovation, the HD Rocksand™. The HD Rocksand is a lightweight, portable, and easy-to-use solution for heavy metal detection in soil, saving users time and money.

By using patented Doubly Curved Crystal (DCC) optics, the HD Rocksand is able to deliver best-in-class limits of detection that enable users to conserve time and money by reducing the number of inconclusive samples that require validation by off-site laboratory methods.

“We’re excited about the significant time and cost savings that the HD Rocksand provides users,” XOS Product Manager, Kyle Kuwitzky said. “The ultra-low levels of detection coupled with the ease of use make the HD Rocksand a total solution for heavy metal soil analysis.”

Brownfield sites are often very large and users often need to move around the entire site to collect measurements. With that in mind, XOS engineered the HD Rocksand to be highly portable, integrating a comfortable handle with a lightweight design that is conducive to easy movement and efficient soil analysis.

Additionally, HD Rocksand provides flexible measurement for simple soil analysis. The analyzer allows for the measurement of bagged and core samples using a hands-free, push-button feature.

For samples that require the highest precision on par with results from laboratory methods, a sample cup rotation feature is included to make accurate measurements of heterogeneous samples. Additionally, pit walls and large samples that do not fit in the portable test stand can be tested using the handheld measurement option without the need to prepare a smaller portion of the sample.

To learn more about how the XOS HD Rocksand analyzer can help you conserve time and money with powerful heavy metal detection in soil, please visit us online at or call 1-888-675-8099 FREE.

About XOS

XOS is a leading manufacturer of application-specific X-ray analyzers, offering elemental analysis solutions that improve public safety and customer efficiency in industries like petroleum, consumer products, and environmental compliance. For petroleum applications, XOS offers portable, lab, and process analyzers with unrivalled precision at the push of a button. XOS also offers High Definition XRF (HDXRF©) analyzers for the detection of toxic elements in consumer products, such as toys and apparel and areas of environmental regulation, like soil and water. XOS’s advanced optics and OEM sub-systems can increase precision, speed, and spatial resolution, while decreasing the size, complexity, and cost of the instrument.
Source: XOS

Written by asiafreshnews

June 15, 2015 at 11:38 pm

Posted in Uncategorized

New Xultophy(R) (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change and Lower Rate of Hypoglycaemia Versus Insulin Glargine

leave a comment »

BOSTON, June 8, 2015 /PRNewswire/ —

– 166-OR

This material is intended for medical non-UK media only.

For journalistic assessment and preparation before publication.

New phase 3b findings showed adults with type 2 diabetes treated with Xultophy® (IDegLira), a once-daily, single-injection combination of insulin degludec and liraglutide, demonstrated statistically significant reduction in HbA1c(average blood glucose over the previous three months), change in body weight and a lower rate of hypoglycaemia compared with patients treated with insulin glargine.[1]

To view the Multimedia News Release, please click:

Findings from the phase 3b DUAL™ V 26-week trial that compared the efficacy and safety of Xultophy® versus insulin glargine, both added on to metformin, in patients with type 2 diabetes uncontrolled on insulin glargine (20-50 units/day), were presented today at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, United States.[1]

At 26 weeks, patients randomised to Xultophy® treatment achieved a statistically significant mean reduction in HbA1c of 1.8% from baseline (8.4% to 6.6%) compared with a 1.1% reduction (8.2% to 7.1%) achieved by patients who further increased their dose of insulin glargine (p<0.001).[1] In the Xultophy® group, 72% of patients achieved an HbA1c of <7% at the end of the trial, compared with 47% of patients in the insulin glargine group (p˂0.001).[1] Furthermore, 39% of patients treated with Xultophy® achieved an HbA1c <7% without hypoglycaemia and weight gain versus 12% treated with insulin glargine (p<0.001).[1]

"The results demonstrated that IDegLira treatment could positively impact patients who are not in control on their current basal insulin therapy," said Professor John Buse, University of North Carolina School of Medicine, Chapel Hill, North Carolina, US. "IDegLira patients achieved an end of trial mean HbA1c of 6.6% while still experiencing weight reduction, and had significantly less hypoglycaemia than patients taking higher doses of insulin glargine."

There was a 57% lower rate of confirmed hypoglycaemia with Xultophy® compared with insulin glargine (2.23 episodes/patient-year vs 5.05 episodes/patient-year; p<0.001).[1] Additionally, there was a significant difference of 3.2 kg (7.1 lb) in change in body weight between treatment groups (p<0.001); body weight decreased by 1.4 kg (3.0 lb) from baseline for patients treated with Xultophy® and increased by 1.8 kg (4.0 lb) for patients treated with insulin glargine.[1] Patients treated with Xultophy® required significantly less insulin than patients treated with insulin glargine, demonstrated by the end-of-trial dose of 41 units of the insulin degludec component in Xultophy® versus 66 units respectively (p<0.001).[1]

In the DUAL™ V trial, there were similar rates of overall and serious adverse events in the two treatment groups.[1]

Also presented during the scientific meeting were additional patient-reported outcomes (PRO) data measured by TRIM-D (Treatment Related Impact Measure-Diabetes) and SF36 v2 (Short-Form 36 Health Survey version 2) from DUAL™ V:

Insulin Degludec/Liraglutide (IDegLira) Improves Patient-Reported Impacts in Subjects With Type 2 Diabetes (T2D) Inadequately Controlled on Insulin Glargine (IG) Plus Metformin (Met): DUAL™ V Study (Abstract #2550-PO).

About Xultophy®

Xultophy® is a once-daily single injection combination of Tresiba® (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration of action and Victoza® (liraglutide), a once-daily human GLP-1 analogue.[2] The maximum dose of Xultophy® is 50 dose steps (equivalent to 50 units of insulin degludec and 1.8 mg of liraglutide). Xultophy® is being investigated in the DUAL™ clinical trial programme which includes two phase 3a and a number of phase 3b trials, encompassing more than 3,500 people with type 2 diabetes. Xultophy® was granted marketing authorisation by the European Commission on 18 September 2014 and approved in Switzerland on 12 September 2014.[2],[3]

About DUAL™ V

DUAL™ V was a phase 3b, 26-week, treat-to-target, randomised, open-label, multicentre trial conducted in 10 countries with 557 patients. The trial was designed to show non-inferiority in HbA1c and to subsequently demonstrate superiority in HbA1c, body weight and hypoglycaemia. The trial compared the efficacy and safety of Xultophy® versus insulin glargine, both added on to metformin, in adults with type 2 diabetes uncontrolled on insulin glargine (20-50 units). The pre-trial mean dose of insulin glargine was 32 units. Patients could be titrated to the maximum dose of Xultophy® (equivalent to 50 units of insulin degludec and 1.8 mg of liraglutide) and there was no maximum daily dose of insulin glargine.[1],[4]

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,000 people in 75 countries and markets its products in more than 180 countries. For more information, visit, Facebook, Twitter, LinkedIn, YouTube



Buse J, et al . Insulin Degludec/Liraglutide (IDegLira) is Superior to Insulin Glargine (IG) in A1c reduction, Risk of Hypoglycaemia and Weight Change: DUAL V Study. Oral presentation (#166-OR) at the 75th Scientific Sessions of the American Diabetes Association (ADA), 7 June 2015.


EMA. Xultophy® Summary of Product Characteristics. Available at: Last accessed: 03.02.2015.


SwissMedic. Xultophy®: Information for Professionals. 22.09.2014.

4 NCT01952145. A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V). Available at: Last accessed: 03.02.2015.

Source: Novo Nordisk A/S

Written by asiafreshnews

June 15, 2015 at 11:16 pm

Posted in Uncategorized

CSA Group expands European hazardous locations testing and certification services with new office in Hannover, Germany

leave a comment »

FRANKFURT, Germany, June 8, 2015 /PRNewswire/ — CSA Group, a global provider of testing and certification services and a leading standards development organization, has opened an office in Hannover (Germany) which will be focussing on hazardous locations (hazloc) testing and certification as well as on functional safety. The new team includes Herbert Peters and Gordon Neuroth, both of whom are well-established experts in hazardous locations testing and certification in the German market. They will work very closely with CSA Group’s global hazardous locations team to provide certification and associated services to German clients.

“CSA Group is very pleased to expand our certification service offerings in Europe with our new Hannover office and the addition of outstanding experts to the team,” said Ralf Schunk, CSA Group Regional Vice President Europe. “We have an incredible demand in Germany from the oil sector as well as from the chemical and petrochemical industry, and we will now be able to provide local services to our clients in Germany.”

The Hannover office is integrated with CSA Group’s new state-of-the-art hazardous locations laboratory in Hawarden, UK, which opened in May 2015. The new Hawarden laboratory utilises the latest equipment and techniques and is one of the most comprehensive international standards compliance testing facilities in the world. The laboratory supports compliance testing needs and offers Ingress Protection (IP) tests, temperature rise testing designed to simulate “real life” conditions, explosion and flameproof test cells, fuel dispenser testing and a “non-metal lab” specifically designed to reduce the risk of sparking. Additionally, CSA Group will continue to invest further in its German labs in Strasskirchen and Frankfurt to provide hazardous locations testing.

CSA Group provides hazardous locations testing and certifications for the European Union, North America, ATEX and IECEx certification. CSA Group has a skilled team of experts in the United Kingdom and is a recognized leader in hazardous locations services worldwide. CSA Group also has hazardous locations testing facilities in Canada, the United States, India and China and hundreds of experienced hazardous locations experts around the world.

The new office is located at CSA Group, Technologie Zentrum im Wissenschaftspark, Hollerithallee 17, 30419 Hannover and can be contacted via phone at +49 511 60068874.

About CSA Group

CSA Group is an independent, not-for-profit membership association dedicated to safety, social good and sustainability. Its knowledge and expertise encompass standards development; training and advisory solutions; global testing and certification services across key business areas including hazardous location and industrial, transportation, plumbing and construction, medical, safety and technology, appliances and gas, alternative energy, lighting and sustainability; as well as consumer product evaluation services. The CSA certification mark appears on billions of products worldwide. For more information about CSA Group visit

For further information, contact:
Allison Hawkins
Manager, Corporate Affairs

Source: CSA Group

Written by asiafreshnews

June 15, 2015 at 5:50 pm

Posted in Uncategorized

TFWA: Strong Visitor Figures for Regional Duty Free and Travel Retail Event

leave a comment »

SINGAPORE, June 8, 2015 /PRNewswire/ — TFWA Asia Pacific Exhibition & Conference 2015, the 20th event for the duty free & travel retail industry in Asia Pacific, closed on 14th May in Singapore after a very successful week.

To view the Multimedia News Release, please click:

With occupied exhibition space topping previous years at 9,118 m2 – up 9% on 2014 – and 292 exhibiting companies present (+12%), of which 73 were new to the show, there was a huge variety of products on display for the benefit of visiting buyers and agents.

Visitor numbers were considered satisfactory by organisers TFWA in a year which has been challenging for the duty free and travel retail industry, with aviation accidents, a new approach to gift giving and luxury consumption among the all-important Chinese travellers, financial instability and political tension in several countries and the resulting slowdown in the growth of air passenger traffic.

A total of 2,655 trade visitors attended the show, equivalent to last year, from 1,053 companies (+3%) of which more than a third were “key buyers” – duty free & travel retail operators and landlords from airports, airlines, ferry and cruise companies, cross-border and downtown duty free stores.

“I was very impressed by the quality of the stands, the assortment of products on display and the energy around the show,” said Erik Juul-Mortensen, President TFWA. “This year has not been easy for the industry in this region and, in light of that, we are really very satisfied with the number of companies present and the quality of the visitors.”

Duty free & travel retail sales in the Asia Pacific region in 2014 totalled US$23.6 billion, up 5.5% on the previous year, according to provisional figures from independent analysts Generation Research, which ranks the region top in the global industry with 38% of total sales. The second largest region is Europe, followed by Americas, Middle East and Africa.

Forthcoming events organised by TFWA include TFWA World Exhibition & Conference from 18th to 23rd October 2015 in the Palais des Festivals, Cannes and the Middle East & Africa Duty Free Association Conference from 22nd to 24th November 2015 at the King Hussein Bin Talal Convention Centre, Dead Sea, Jordan. Details of these events can be found at

(Photo: )

Source: TFWA

Written by asiafreshnews

June 15, 2015 at 5:44 pm

Posted in Uncategorized

Young Football Players From 24 Countries of Europe and Asia Meet at Third International Children’s Football for Friendship Forum

leave a comment »

BERLIN, June 8, 2015 /PRNewswire/ — Today Berlin hosted the Third International Children’s Forum organised within the Gazprom social Football for Friendship program. The program is aimed at developing youth football and promoting universal human values among children and teenagers. The event gathered young players from the best football clubs of 24 European and Asian countries: Austria, Belarus, Belgium, Bulgaria, China, Croatia, Czech Republic, France, Japan, Germany, Hungary, Italy, Kazakhstan, the Netherlands, Poland, Russia, Serbia, Slovak Republic, Slovenia, Spain, Switzerland, Turkey, Ukraine, and the United Kingdom.

(Logo: )
(Photo: )

A total number of Forum participants is 670 people. Totally, in 2015 the Football for Friendship program has been globally supported by more than 100,000 children and adults, including famous sportsmen and artists.

During the Forum children have an opportunity to communicate with their peers from other countries and football stars including the global Ambassador of the program Franz Beckenbauer as well as to participate in the International Street Soccer Tournament among youth football teams.

Forum events are covered by around 200 journalists of the major global media as well as 24 young reporters from Europe and Asia who joint the International Children’s Press Centre.

The Forum culminated with awarding of Nine Values Cup that was given by young participants of Football for Friendship to professional clubs of the UEFA Champions League for social projects that practically perform values of the program: friendship, equality, fairness, health, peace, devotion, victory, traditions and honour. This unique trophy with no analogue in sports community was presented for the first time. The winner was chosen by children who had taken part in global 24-country voting held shortly before the Forum.

Football for Friendship Nine Values Cup went to FC Barcelona. Children marked club’s initiatives in support and development of youth football as well as help for young footballers from developing countries.

After the Forum all the participants traditionally visit the UEFA Champions League Final.

The FOOTBALL FOR FRIENDSHIP project is being operated globally by AGT Communications Group (Russia).
Source: The International Children’s Social FOOTBALL FOR FRIENDSHIP project press center

Written by asiafreshnews

June 15, 2015 at 5:31 pm

Posted in Uncategorized

Merck, Illumina and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment

leave a comment »

DARMSTADT, Germany, June 8, 2015 /PRNewswire/ —

Not intended for US based media

Global Fertility Alliance will identify and work on improvements of fertility-related laboratory processes

Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. The alliance is a partnership between Merck Serono, the biopharmaceutical business of Merck, Illumina Inc., San Diego, US, a leader in developing and commercializing systems for analysis of genetic variation and function, and Genea Limited, Sydney, Australia, which develops innovative fertility technologies.

(Logo: )

“We are the global leader in the field of fertility drugs and committed to supporting the success and improvement in ART by going beyond drugs with innovative technologies,” explained Meeta Gulyani, Head of Global Strategy and Franchises at Merck Serono. “By forging the Global Fertility Alliance with partners like Illumina and Genea we aim to support the development of needed global standards in ART labs. This will ensure a consistently high level of performance between different centers and countries.”

The alliance aims to improve the consistency in ART worldwide and addresses the need for more standardization of fertility processes within the ART laboratory. The three companies will launch their initiative at the 31st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Lisbon, Portugal, on 13 June 2015. This is another important step for Merck Serono towards establishing global standards in the growing market of fertility technologies and the ultimate goal of helping families to have a baby.

With the establishment of the alliance, Merck Serono, Illumina and Genea emphasize their desire to help improve fertility outcomes by contributing to the standardization of technologies and protocols in ART labs. Currently, variation in practices and techniques can lead to inconsistent results and outcomes. Recognizing the importance of innovation in ART technologies the alliance aims to enhance progress and innovation in three ways: Firstly, the founding members aim to foster integration of multiple, leading fertility technologies. Secondly, building on this, the alliance will aim to collaborate with leading health care professionals and medical societies to develop global standards. And finally, as technologies in the fertility space are rapidly advancing, the alliance will also develop educational resources for health care professionals worldwide. These efforts will include training curricula and workshops as well as access to model labs, symposia and events at medical meetings.

Illumina’s Senior Vice President and General Manager of Reproductive and Genetic Health, Tristan Orpin, also highlighted the significance of the alliance for the reproductive biology community: “Illumina has a strong commitment to improving in vitro fertilization (IVF) outcomes through the use of industry leading genomics but appreciates that there are many factors that impact ART outcomes. Founding the Global Fertility Alliance together with Merck Serono and Genea represents an exciting opportunity for us to share our knowledge and experience with the wider community and to help bring alignment and higher consistency to ART practices worldwide. Having already partnered with Merck Serono in other treatment areas, we are confident this collaboration of innovators in the fertility field will deliver a significant positive impact for health care professionals, fertility labs, and most importantly their patients.”

“Increasing success rates for patients worldwide and advancing the science of fertility treatment is an integral part of our mission,” said Tomas Stojanov, CEO of Genea. “The new Global Fertility Alliance for excellence in ART will drive automation and standardization in the field and support health care professionals in providing their patients with the best possible outcomes.”

In order to rapidly progress the initiative, Merck Serono, Illumina and Genea will actively contribute to the alliance and establish a board of representatives, which will meet regularly. At the same time, the companies invite new members, who demonstrate a consistent commitment to driving technology innovation and improving ART results, to join the alliance.

About Genea

Genea is a fertility pioneer, researching, developing and introducing breakthrough techniques and technologies in assisted reproductive treatment for almost 30 years. Genea is a strongly interconnected group of three companies:

Genea Fertility has clinics across Australia, as well as in New Zealand and Thailand.

Genea Biomedx creates and manufactures practical, accessible and precise fertility technologies that help standardise and automate fertility treatment. Its unique relationship with Genea Fertility means that Genea Biomedx is a manufacturer that truly understands the customers’ perspective. As a result Genea Biomedx has developed the world’s first automated vitrification instrument, and has other projects well advanced in the product pipeline.

Genea Biocells develops unique disease-specific and unaffected human pluripotent stem cell platforms, differentiated cells, including the first robust skeletal muscle differentiation platform; culture media and small molecule libraries for use in research, drug development and cell therapy. Genea Biocells partners with scientists in industry and academia to advance innovative projects using chemical biology and stem cell-driven approaches.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of around EUR 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

Source: Merck Serono

Written by asiafreshnews

June 15, 2015 at 5:08 pm

Posted in Uncategorized

BioAtla Receives $30 Million Equity Investment From China-based Investor Group

leave a comment »

— Proceeds to accelerate proprietary product development and to create opportunities in China pharmaceutical market

SAN DIEGO /PRNewswire/ — BioAtla LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that a China-based investor group has purchased $30 million in BioAtla equity. The proceeds will be used to accelerate the development of the company’s CAB antibody drug pipeline. This strategic investment also will advance BioAtla’s plans to collaboratively develop biotherapeutics with biopharmaceutical companies and institutions in China to address the high demand for innovative therapeutic products and the growing demand in the Chinapharmaceutical market.

BioAtla’s patent protected Conditionally Active Biologics platform represents a disruptive technology for the development of a powerful new class of immunotherapeutics that are activated in selected microenvironments within the body, such as those indicative of cancerous tumors. CABs can be generated in several different formats including naked monoclonal antibodies (mAbs), antibody drug conjugates, immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T cells.

“The $30 million equity investment is a transformative event for BioAtla and our strategy to broadly and rapidly pursue novel therapeutic products based on our patented CAB and other proprietary technologies,” said Jay M. Short, Ph.D., president, chief executive officer and chairman of the board of BioAtla. “Since BioAtla’s founding in 2007, we have utilized our Beijing development and operations capabilities to successfully develop dozens of protein products under contract and shared development. Our drug development experience and expertise inChina, the great prospects of the CAB platform, and our strategy of proprietary drug development through defined value inflection points prior to partnering with pharmaceutical companies are attractive features for the investor group. The investor group’s contacts and relationships in the China biopharmaceutical field are expected to lead to additional near-term, non-dilutive research and development investments in establishing integrated strategic partnering collaborations in China in the areas of CAB-enhanced antibody therapeutics, including in immuno-oncology and CAR T therapeutics.”

About Conditionally Active Biologics (CABs)

Conditionally Active Biologic proteins (CABs) are generated using BioAtla’s proprietary protein evolution and expression technologies. These proteins can be mAbs, enzymes and other proteins designed with functions dependent on changes in microphysiological conditions (e.g., pH level, oxidation, temperature, pressure, presence of certain ions, hydrophobicity and combinations thereof).

Studies have shown that cancerous tumors create highly specific conditions at their site that are not present in normal tissue. These cancerous microenvironments are a result of the well understood unique glycolytic metabolism associated with cancer cells, referred to as the Warburg Effect, which was first described in the early 1900’s and is the basis of the widely-used PET scan cancer detection method today. CAB-designed mAbs can be programmed to deliver their therapeutic payload and/or recruit the immune response in specific and selected locations and conditions within the body. CABs increase safety because the drug is reversibly activated when it preferentially binds directly to its intended target protein in the area of disease. In this example, the CAB does not effectively bind to the same protein located in healthy tissue or other part of the body that otherwise results in undesirable toxicity.

The CAB antibody’s selective activation results from amino acid substitutions of human-like sequences made to ensure compatibility. In addition to reducing risk of immunogenicity, this approach also improves the manufacturing yield of the drug. Reliably good expression and high manufacturing yields are also derived from BioAtla’s patented Comprehensive Integrated Antibody Optimization™ (CIAO) technology that allows every step of development and screening of antibody variants through final CAB lead selection to be conducted in the mammalian cell type to be used in manufacturing.

CABs allow for higher dosing, the development of effective, non-immunogenic drugs, and the use of targets that are validated for cancer cells but traditionally considered too prevalent among normal cells to be used safely in current drug therapies. This opens a potentially rich range of targets for CABs that cannot be addressed using existing technologies. CABs may also be employed as diagnostic tools to reveal and pinpoint conditions indicative of cancerous activity.

About BioAtla, LLC

BioAtla is a global biotechnology company with operations in San Diego, California, and Beijing, China. BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing. By utilizing its proprietary technologies of product design and development, from target discovery to manufacturing and preclinical studies, BioAtla develops differentiated, patentable therapeutic proteins for its partners and for its internal programs. BioAtla has over 100 patents issued and pending that cover its platform technologies representing a full complement of therapeutic protein development capabilities. Learn more at


Richard Waldron
Chief Financial Officer
BioAtla LLC

Source: BioAtla LLC
Related Links:

Written by asiafreshnews

June 15, 2015 at 4:51 pm

Posted in Uncategorized

Bone Health Starts in the Womb, So Good Nutrition Key to Strong Bones Through Life

leave a comment »

NYON, Switzerland, June 8, 2015 /PRNewswire/ —

Official launch of World Osteoporosis Day – celebrated on October 20 – puts the spotlight on the importance of bone-healthy nutrition from early life through to adulthood

Today saw the launch of the 2015 World Osteoporosis Day (WOD) campaign organized by the International Osteoporosis Foundation (IOF). Celebrated on October 20, this year’s theme focuses on Nutrition and addresses the public health challenges associated with insufficient intake of calcium, vitamin D and protein as well as other micronutrients crucial to bone health.


The majority of people are not getting their recommended daily allowances of calcium and vitamin D. In fact, worldwide, an estimated 1 billion people have inadequate levels of vitamin D in their blood, and deficiencies can be found in all ethnicities and age groups. In China, estimates from the Health Status Survey in 2002 indicated that less than 10% of Chinese citizens had an adequate dietary intake of calcium. Chronic untreated calcium deficiency can have many severe consequences, including osteopenia and osteoporosis.

Osteoporosis has been defined as ‘a paediatric disease with geriatric consequences’, emphasizing that bone health is shaped very early in life; in fact in the womb. Poor nutritional status of the mother can impact on the optimal growth of the baby’s skeleton. It has been associated with reduced adult bone mineral content at peak bone mass and in later life, as well as increased risk of hip fracture.

Beyond this, childhood and adolescence is a critical time for bone building as during this period both the size and strength of our bones increases significantly. Approximately half of our bone mass is accumulated during adolescence. This process continues until the mid-20s when peak bone mass is generally achieved (the maximum amount of bone possible during skeletal growth).

Helping a child achieve optimal bone strength is beneficial in late adulthood as there is more bone in reserve from which to draw; unlike in their younger years adults cannot replace bone tissue as quickly as they lose it. It is believed that a 10% increase in peak bone mineral density (BMD) – one measure of bone strength – could delay the development of osteoporosis by 13 years.

Prof. John Kanis, President, IOF, said “Our skeleton is very much like a house. It needs to be built with the right material to keep the structure strong and maintained over time to avoid any long-term damage. That’s why eating foods such as dairy products, oily fish, fruits and vegetables will provide us with the essential nutrients that are the key building blocks of strong bones.”

Judy Stenmark, CEO, IOF added that “99% of the 1 kg of calcium found in the average body resides in our bones, which highlights why we need to get our recommended daily intake as fuel for the production and maintenance of bone. I encourage everyone to take the IOF Calcium Calculator test to find out how much calcium they are getting and how they can boost their intake.”

Calcium Calculator available for free as:

Online calculator:

iPhone App:

Android App:

WOD, observed annually on 20 October, marks a year-long campaign #LoveYourBones

WOD Official Partners: Amgen, Fonterra, Pfizer Consumer Healthcare, Lilly, MSD, Takeda

WOD Nutrition Supporters: DSM, Rousselot, Sunsweet

About International Osteoporosis Foundation

IOF is the world’s largest NGO dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases.

Media contact
Charanjit K. Jagait, IOF, Phone +41-79-874-52-08,
Source: The International Osteoporosis Foundation (IOF)

Written by asiafreshnews

June 15, 2015 at 4:51 pm

Posted in Uncategorized

Boost Your Business: Should Small Businesses Adopt Wearable Technology?

leave a comment »

-Newest article on PR Newswire’s Small Business PR Toolkit provides questions to ask to prepare for the rise of wearables

NEW YORK /PRNewswire/ — As the interest of wearable technologies by consumers continues to grow, small business owners are beginning to collect data that can uncover how they can leverage these platforms in order to support their brand’s products and services. While they may be taking a more reserved approach than larger corporations, small businesses should still consider asking the following questions when determining how wearables can impact your business performance:

  • Do I now have to create a wearable technology app?

Don’t create a wearable app just for the sake of creating one. In order for a wearable app to be useful, it will need to provide some value in a way that a smartphone currently cannot.

  • Do I need to establish a policy to accommodate users or non-users of wearable technology?

This question not only relates to customers, but also your employees and vendors. Clearly identifying how these platforms can affect interactions with all the elements of your business can help to pave the way for integration. Will you need to accommodate the changing behaviors, and if so should you document and share with all employees?

To discover other questions you should ask on how wearables can impact your business, read contributing author Heather Wied’s latest post here:

Logo –

PR Newswire’s Small Business PR Toolkit is a comprehensive resource that provides small businesses and entrepreneurs the tools to develop an affordable public relations and marketing plan that helps generate interest from potential customers, engage with key audiences and grow their businesses. The toolkit features relevant content such as informative white papers, interactive webinars and how-to articles and premium access to educational resources, as well as the opportunity to take advantage of special offers designed specifically for small businesses. To request information on how PR Newswire can help your small business, click here. You can receive updates on new Small Business PR Toolkit content by following @prnsmallbiz on Twitter.

About PR Newswire
PR Newswire ( is the premier global provider of multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry over 60 years ago, PR Newswire today provides end-to-end solutions to produce, optimize and target content — from rich media to online video to multimedia — and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world’s largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world’s enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a UBM plc company.

Amanda Eldridge
Director, Strategic Channels

Source: PR Newswire Association LLC

Related stocks: LSE:UBM OTC-PINK:UBMPY

Written by asiafreshnews

June 15, 2015 at 4:45 pm

Posted in Uncategorized

MediaCom Named World’s Leading Media Agency

leave a comment »

-Client loyalty and new business record contribute to global recognition

LONDON /PRNewswire/ — MediaCom has been recognized as the world’s leading media agency by RECMA, the independent research organization charged with the in-depth assessment of global media agency network performance.

Logo –

The results were published this week in RECMA’s authoritative Network Diagnostics report, with MediaCom ahead of Carat, OMD and Starcom across 19 key qualitative metrics designed to measure agency vitality and structural ability to address today’s complex communications challenges.

MediaCom’s top position is underpinned by its recent new business success across a number of networked clients, with marquee client wins including Mars worldwide planning, The Coca-Cola Company assignment inMexico and the highly-coveted AB Inbev account in the US.  Momentum in the US, the largest market for all players in the industry, has resulted in MediaCom being named 2015 U.S. Media Agency of the Year by both Advertising Age and Adweek.

The full RECMA qualitative assessment is based on MediaCom’s performance across 40 markets in not only pitch competitiveness, but also client loyalty, top management, digital resources and awards, reflecting the agency’s proven performance in delivering superior results for global clients such as The Coca-Cola Company, Procter & Gamble and SONY.

The no. 1 accolade comes at a time of unprecedented change in the industry, with a large number of major accounts currently in review.  MediaCom’s structural readiness, as detailed by RECMA’s report, enables it to compete ongoing without destabilizing existing relationships.

“We’ve worked incredibly hard over the last few years to consistently build the global scale and expertise it takes to commit 100% to all our clients while still winning new business,” said Stephen Allan, Worldwide Chairman and CEO of MediaCom.  “With more brands looking to marketing to drive business growth, our Content + Connections positioning and systems thinking approach enables us to provide a unique level of guidance and maximize client shareholder return.”

For media enquiries, please contact:
Joanne Brenner

About MediaCom

MediaCom is the “The Content + Connections Agency”, working on behalf of its clients to leverage their brands’ entire system of communications across paid, owned and earned channels to step change their business outcomes.  MediaCom delivers not just individual channel silo efficiencies but also connected communications system effectiveness, by developing and optimising all content – defined as any form of consumer messaging – as the fuel that drives high-performing systems. MediaCom measures and quantifies communications systems across paid, owned and earned through their unique Connected System Audit.

MediaCom is one of the world’s leading media communications specialists, with billings exceeding US$29 billion(Source: RECMA 2013). It employs 6,000 people in 125 offices across 100 countries around the globe.  Its client roster includes P&G, VW Group, Dell and Universal.  MediaCom was named Network of the Year at the Global M&M Awards for an unprecedented fourth year 2013, 2011, 2010 and 2009.

MediaCom is a member of WPP, the world’s largest marketing communications services group, and part of GroupM, WPP’s consolidated media investment management arm.

For more information, visit
Find us on Twitter @mediacomglobal.
Like us on Facebook at
Join us on LinkedIn at

About GroupM

GroupM is the leading global media investment management operation. It serves as the parent company to WPP media agencies including Mindshare, MEC, MediaCom and Maxus, as well as Xaxis and Catalyst. Our primary purpose is to maximize the performance of WPP’s media communications agencies on behalf of our clients, our stakeholders and our people by operating as a parent and collaborator in performance-enhancing activities such as trading, content creation, sports, digital, finance, proprietary tool development and other business-critical capabilities. The agencies that comprise GroupM are all global operations in their own right with leading market positions. The focus of GroupM is the intelligent application of physical and intellectual scale to benefit trading, innovation, and new communication services, to bring competitive advantage to our clients and our companies. Discover more about us online at

About WPP

WPP is the world’s largest communications services group with billings in 2013 of US$72.3 billion and revenues of US$17.3 billion.  Through its operating companies, the Group provides a comprehensive range of advertising and marketing services including advertising & media investment management; data investment management; public relations & public affairs; branding & identity; healthcare communications; direct, digital, promotion & relationship marketing and specialist communications. The company employs over 179,000 people (including associates) in over 3,000 offices across 111 countries.  For more information, visit

WPP was named Holding Company of the Year at the 2014 Cannes Lions International Festival of Creativity for the fourth year running. WPP was also named, for the third consecutive year, the World’s Most Effective Holding Company in the 2014 Effie Effectiveness Index, which recognizes the effectiveness of marketing communications.

Source: MediaCom

Written by asiafreshnews

June 15, 2015 at 4:41 pm

Posted in Uncategorized